These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Sustained Response to Vemurafenib in a BRAF Prager GW; Koperek O; Mayerhoefer ME; Muellauer L; Wrba F; Niederle B; Zielinski CC; Raderer M Thyroid; 2016 Oct; 26(10):1515-1516. PubMed ID: 27532222 [No Abstract] [Full Text] [Related]
6. Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer. Wei WJ; Sun ZK; Shen CT; Song HJ; Zhang XY; Qiu ZL; Luo QY Theranostics; 2017; 7(4):987-1001. PubMed ID: 28382170 [TBL] [Abstract][Full Text] [Related]
7. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Hong DS; Morris VK; El Osta B; Sorokin AV; Janku F; Fu S; Overman MJ; Piha-Paul S; Subbiah V; Kee B; Tsimberidou AM; Fogelman D; Bellido J; Shureiqi I; Huang H; Atkins J; Tarcic G; Sommer N; Lanman R; Meric-Bernstam F; Kopetz S Cancer Discov; 2016 Dec; 6(12):1352-1365. PubMed ID: 27729313 [TBL] [Abstract][Full Text] [Related]
8. Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells. Cheng W; Liu R; Zhu G; Wang H; Xing M J Clin Endocrinol Metab; 2016 Mar; 101(3):962-71. PubMed ID: 26751190 [TBL] [Abstract][Full Text] [Related]
9. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells. Luo H; Umebayashi M; Doi K; Morisaki T; Shirasawa S; Tsunoda T Anticancer Res; 2016 Jul; 36(7):3585-9. PubMed ID: 27354627 [TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495 [TBL] [Abstract][Full Text] [Related]
11. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Ravnan MC; Matalka MS Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884 [TBL] [Abstract][Full Text] [Related]
12. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. Joshi M; Rice SJ; Liu X; Miller B; Belani CP PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985 [TBL] [Abstract][Full Text] [Related]
13. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition. Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083 [TBL] [Abstract][Full Text] [Related]
14. Vemurafenib: a guide to its use in unresectable or metastatic melanoma. Keating GM; Lyseng-Williamson KA Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082 [TBL] [Abstract][Full Text] [Related]
17. BRAF V600E inhibition in anaplastic thyroid cancer. Rosove MH; Peddi PF; Glaspy JA N Engl J Med; 2013 Feb; 368(7):684-5. PubMed ID: 23406047 [No Abstract] [Full Text] [Related]
18. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment. Protsenko SA; Semionova AI; Komarov YI; Aleksakhina SN; Ivantsov AO; Iyevleva AG; Imyanitov EN Invest New Drugs; 2015 Oct; 33(5):1136-43. PubMed ID: 26286452 [TBL] [Abstract][Full Text] [Related]
19. mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib. Hanly EK; Bednarczyk RB; Tuli NY; Moscatello AL; Halicka HD; Li J; Geliebter J; Darzynkiewicz Z; Tiwari RK Oncotarget; 2015 Nov; 6(37):39702-13. PubMed ID: 26284586 [TBL] [Abstract][Full Text] [Related]
20. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]